Buy or sell Pathway Genomics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Pathway Genomics Stock

Genetic DNA Testing Company

Founded

2008

Notable Investors

IBM Ventures

Headquarters

San Diego CA, US

Total Funding

$43.0M

About Pathway Genomics Stock

Pathway Genomics provides a comprehensive set of genomic testing services across the healthcare spectrum, including tests for general health and wellness, liquid biopsy, pharmacogenomics, hereditary cancer risk and carrier screening. Its general health and wellness tests, including PathwayFit®, Cardiac DNA Insight®, and SkinFit™, equip physicians and patients with genetic information to support lifestyle choices. Liquid biopsy tests, including CancerIntercept™ Detect and Monitor, are non-invasive tests for detection of circulating tumor DNA. Pathway’s pharmacogenomics tests (Mental Health DNA Insight® and Pain Medication DNA Insight®) provide genetic information to help guide selection of optimal medication for management of mental health and pain disorders. Pathway’s hereditary cancer risk tests, including BRCATrue® and ColoTrue®, evaluate genetic factors for future cancer risk. Pathway Genomics Corporation operates a clinical laboratory to provide its commercial genetic testing services to physicians and their patients in the United States and internationally. Pathway Genomics Corporation was incorporated in 2008 and is based in San Diego, California.

Investors

Funding History

July 2009$3.0M
January 2016$40.0M

Management

Chief Laboratory Officer & Medical Director

Nilesh Dharajiya, M.D.

Chief Business Officer

K'Lene Oen

Chief Financial Officer

Kamal Adawi

Executive Vice President, Domestic Sales

Anthony Facinelli

Chief Scientific Officer

Anja Kammesheidt, Ph.D.

Vice President of Business Development and Government Relations

Mitch Mulanix

Chief Medical Officer

Glenn D. Braunstein, M.D.

Founder and CEO

James Plante

Chief Privacy and Compliance Officer

Michael H. Cox, CIPP

Chief Innovation Officer

Michael Nova, M.D.

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Pathway Genomics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 140K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo